Therapeutic Advances in Vaccines and Immunotherapy最新文献

{"title":"Pediatric asthma and COVID-19 vaccination: unveiling patterns of hesitancy and acceptance.","authors":"Marzieh Tavakol, Saber Gharagozlou, Mohammad Abbasi, Zahra Zamani, Mohammad Gharagozlou","doi":"10.1177/25151355241297874","DOIUrl":"10.1177/25151355241297874","url":null,"abstract":"<p><strong>Background: </strong>The global COVID-19 pandemic, declared in January 2020, necessitated urgent preventive measures, with vaccination as a key strategy. Despite progress in vaccine development and distribution, widespread hesitancy persists, impeding global disease control efforts. This study specifically explores COVID-19 vaccine hesitancy and acceptance among Iranian children with asthma, aiming to understand factors unique to this subgroup.</p><p><strong>Method: </strong>A cross-sectional investigation was carried out in an allergy clinic in Iran, including a total of 522 asthmatic children between the ages of 5 and 18 years. A comprehensive questionnaire, built upon previous studies, investigated the factors that influence vaccine hesitation and acceptance. Data pertaining to demographics, vaccination status, and factors influencing hesitancy or acceptance were collected.</p><p><strong>Results: </strong>Among the participants, 27.5% were administered the COVID-19 vaccine. Decisions were greatly influenced by family dynamics, with a notable association between parent and child vaccination. Children's vaccination rates were associated with their age and the frequency of COVID-19 diagnosis among their parents. The primary factors motivating individuals to get vaccinated were safety concerns (67.1%) and a strong belief in the severity of COVID-19 (43.4%). On the other hand, vaccine hesitancy resulted from concerns about potential adverse effects (77%), lack of confidence (28.3%), and a belief that children who had already contracted COVID-19 did not require vaccination (22.5%).</p><p><strong>Conclusion: </strong>The study highlights COVID-19 vaccine hesitancy and acceptance among asthmatic children in Iran, emphasizing parental decision-making factors. Tailored interventions are required due to the lower vaccination rate in this specific group. Healthcare providers play a vital role in influencing opinions, urging actions against misinformation, enhancing vaccine understanding, and promoting positive attitudes.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241297874"},"PeriodicalIF":0.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping changes in the utilization of childhood immunization over 5 years in a south Indian tertiary care hospital.","authors":"Merrin Mathew, Savitha Rajapur Sanathan, Juny Sebastian, Mandyam Dhati Ravi, Taniya Joy, Rovin Mathew Theempalangad, Panchaksharappa Gowda","doi":"10.1177/25151355241287705","DOIUrl":"10.1177/25151355241287705","url":null,"abstract":"<p><strong>Background: </strong>Altered vaccine demands and uneven utilization patterns in childhood immunization are evident nationwide. These variabilities may stem from a range of internal and external factors influencing parental preferences. Regular checks and balances are necessary to ensure equal accessibility for all sections of society.</p><p><strong>Aim: </strong>To assess the usage trends of childhood vaccines for 5 years (2018-2022) and to monitor instances of delayed/incomplete immunization status within the community.</p><p><strong>Methodology: </strong>This study recorded the utilization trends of all recommended childhood vaccines over a 5-year period using an ambispective design. The immunization details from 3 years (2018, 2019 and 2020) were retrieved retrospectively, while those from 2 years (2021-2022) were collected prospectively through the immunization registry. Trends in childhood vaccine utilization were recorded across different years, and delays and incomplete vaccine utilization among children, along with factors resulting in deviated immunization timelines, were analysed and compared. The association of factors with deviated immunization utilization was determined using the chi-square test, and a two-way ANOVA analysed utilization variabilities over 5 years.</p><p><strong>Result: </strong>Overall, the study profiled 32,085 children's (who utilized 87,782 vaccine doses) vaccine utilization pattern for 5 years. Optional vaccines were less utilized (18.12% doses by 25.14% children) compared to mandatory vaccines (81.88% doses utilized by 74.86%). The most utilized mandatory vaccine was oral polio (17.48%) and for optional vaccines, it was measles mumps rubella (MMR; 28.31%). Boys had the highest utilization (55.97%) with a significant male preponderance in optional vaccine utilization (<i>p</i> value <0.05). Overall, there was a 26.12% decline (percent change) in vaccine utilization in 2022 compared to 2018. Among children with delayed immunization timelines (6.02%), 3.38% were on catch-up, and 2.45% were not. The most commonly delayed vaccines were diphtheria + tetanus + pertussis boosters (30.90%), Tdap (26.19%) and MMR vaccines (20.65%). Influenza vaccines (28.08%) were the most partially utilized optional vaccine, followed by varicella vaccines (20.92%). Factors such as gender (female), age over 1 year, rural residence and low- to middle-income families were significant predictors of deviated immunization status in children.</p><p><strong>Conclusion: </strong>The study mapped the utilization trends of immunizations at a tertiary care hospital in south India over the past 5 years, including the COVID-19 years. Gender inequality in the utilization of optional vaccines is a concern that warrants further research and redressal. Timely administration of childhood vaccinations is crucial for reducing susceptibility to vaccine-preventable diseases and promoting overall well-being.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241287705"},"PeriodicalIF":0.0,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccination in children aged 5-11: a systematic review of parental barriers and facilitators in Western countries.","authors":"Stephanie A Davey, Daniel Gaffiero","doi":"10.1177/25151355241288115","DOIUrl":"https://doi.org/10.1177/25151355241288115","url":null,"abstract":"<p><strong>Background: </strong>Parental decision-making regarding vaccination, particularly for coronavirus-19 (COVID-19) where significant debate surrounds children aged 5-11, is influenced by various factors. Understanding the motivations behind parents' vaccination choices for their children is crucial for maintaining vaccine uptake, in line with the National Health Service United Kingdom vaccination strategy.</p><p><strong>Objectives: </strong>The present systematic review aims to identify the barriers and facilitators affecting parents' decisions to vaccinate children aged 5-11 against COVID-19 in Western countries.</p><p><strong>Data sources and methods: </strong>The first search was conducted using PsychINFO, MEDLINE and Google Scholar in June 2023 with an additional follow-up search a year later in June 2024 for full-text papers focusing on COVID-19 vaccine decision-making among parents or caregivers of children aged 5-11. The language of the included studies was set as English and originating from Western countries specifically examining barriers and facilitators to COVID-19 vaccination, excluding children with chronic conditions. The risk of bias was independently assessed by both authors using the JBI Checklist for Prevalence Studies, with disagreements resolved through discussion.</p><p><strong>Results: </strong>A total of four cross-sectional questionnaire studies involving a total of 5,812 participants from Western countries (the United States and Europe) were included in the present review. Only 46.35% of parents intended to vaccinate their children aged 5-11 against COVID-19. The primary barriers identified were concerns about side effects and distrust in institutions. Key facilitators included recommendations from healthcare professionals and parents' own COVID-19 vaccination status. Demographic factors including ethnicity and gender showed mixed influence.</p><p><strong>Conclusion: </strong>Persistent concerns about side effects and institutional distrust have reduced parental intention to vaccinate their children. However, healthcare professionals play an important role in increasing vaccine uptake through recommendations to their patients. Future interventions should focus on equipping healthcare professionals with the necessary tools to effectively promote vaccination and address parental concerns about side effects.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241288115"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142476427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Tdap vaccine acceptance in pregnancy before and after delivery.","authors":"David Toubiyan, Joshua Fogel, Allan J Jacobs","doi":"10.1177/25151355241287689","DOIUrl":"https://doi.org/10.1177/25151355241287689","url":null,"abstract":"<p><strong>Background: </strong>Tdap vaccine receipt in the immediate postpartum period has not been well studied.</p><p><strong>Objectives: </strong>We study factors associated with Tdap vaccine receipt during both pregnancy and the immediate postpartum period.</p><p><strong>Design: </strong>Retrospective study of 2844 pregnant patients that delivered.</p><p><strong>Methods: </strong>Factors from demographics, medical history, previous obstetric history, prenatal care, and previous vaccination history were included.</p><p><strong>Results: </strong>39.7% of patients received the Tdap vaccine, 39.5% received the Tdap vaccine prior to delivery, and 20.8% received the Tdap vaccine between delivery and discharge. Increased age (relative risk ratio (RRR): 0.98, 95% CI: 0.96, 0.99, <i>p</i> = 0.01) and lower number of prenatal care visits of fewer than 11 (RRR: 0.51, 95% CI: 0.41, 0.64, <i>p</i> < 0.001) were associated with decreased likelihood of vaccine receipt before delivery. Spanish language (before: RRR: 2.35, 95% CI: 1.69, 3.25, <i>p</i> < 0.001; after: RRR: 1.68, 95% CI: 1.13, 2.49, <i>p</i> = 0.01) and South Asian languages (before: RRR: 1.55, 95% CI: 1.03, 2.32, <i>p</i> = 0.04; after: RRR: 1.69, 95% CI: 1.06, 2.69, <i>p</i> = 0.03) had similar patterns for increased likelihood of Tdap vaccine receipt before and after delivery. Race/ethnicity of Hispanic (RRR:1.84, 95% CI: 1.31, 2.59, <i>p</i> = 0.001), Asian (RRR:1.65, 95% CI: 1.22, 2.22, <i>p</i> = 0.001), and receipt of influenza vaccine during current pregnancy (RRR: 1.58, 95% CI: 1.31, 1.91, <i>p</i> < 0.001) were associated with increased likelihood before delivery.</p><p><strong>Conclusion: </strong>Prenatal Tdap vaccination is the best way to prevent infection with <i>B. pertussis</i>. Postpartum Tdap vaccination provides some protection for those declining prenatal vaccination. We recommend that clinicians recognize that there are different patterns for Tdap vaccine receipt before and after delivery and tailor Tdap vaccine counseling based on these patterns.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241287689"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142476429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine skepticism and vaccine development stages; inoculation from \"cowpox\" lesion to the current mRNA vaccine of COVID-19: review.","authors":"Chernet Tafere, Desalegn Getnet Demsie, Bereket Bahiru Tefera, Adane Yehualaw, Kebede Feyisa, Malede Berihun Yismaw, Ashagrachew Tewabe Yayehrad","doi":"10.1177/25151355241288135","DOIUrl":"https://doi.org/10.1177/25151355241288135","url":null,"abstract":"<p><p>Global pandemics can be tackled by two means: lockdowns and vaccinations. As vaccination has a low impact on economic outcomes and better acceptance by people, it is the preferred method by most governments as a medium- to long-term solution. Vaccines have played a significant role in reducing the global burden of infectious diseases. They are designed to teach the immune system how to fight a particular infection before it causes a disease in subsequent exposures by creating a memory. Although vaccines effectiveness is well known, anti-vaccination movements pose significant challenges, even in high-income settings, leading to outbreaks of life-threatening infectious diseases. Hesitancy to take vaccines is not new and began with the first vaccination of smallpox. At that time, the problem was solved by a regulatory obligation to take vaccines, declared in England and Wales in 1853, which eventually led to its eradication in 1980. Different studies show that there is a decline in awareness of vaccines, hesitancy to take them, and concerns and trust issues regarding healthcare professionals. These problems have been rising over the past few decades for several reasons, notably, because of misinformation spread by social media. Therefore, the objective of this review is to provide a brief overview about vaccine hesitancy and attributable factors, illustrate the different types of vaccines, show the major challenges of vaccine development, and illustrate the pros and cons of each type.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241288135"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142476430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy.","authors":"Ali N Kamali, Haleh Hamedifar, Michael Eisenhut, Jose M Bautista","doi":"10.1177/25151355241288453","DOIUrl":"https://doi.org/10.1177/25151355241288453","url":null,"abstract":"<p><p>Multiple myeloma (MM), a cancer of the bone marrow, is categorized as the second most common hematological malignancy of adults in the Western world. Despite dramatic improvements in immunotherapies in the field of cancers, MM immunotherapy has not been promising until now. Recent clinical studies of immune checkpoint inhibitor therapy, either alone or in combination with anticancer drugs, showed excessive side effects or low efficacy, particularly in advanced MM patients. In this context, lymphocyte levels of exhaustion markers play a pivotal role in the MM tumor microenvironment (TME). Hence in the present review, the mechanisms relevant to MM of five inhibitory molecules including T-cell immunoreceptor with Ig and ITIM domains (TIGIT), T-cell immunoglobulin, and mucin domain 3 (Tim-3), lymphocyte activation gene-3 (LAG-3), V-domain Ig Suppressor of T-cell activation and killer immunoglobulin-like receptors along with bispecific T-cell antibodies (BsAbs) will be discussed. Further, we summarized the underlying biology of these checkpoints in cancer and their rapidly emerging role in pathways in MM along with presenting recent clinical trials in context.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241288453"},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142476428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring COVID-19 vaccine adverse events among pregnant women: a cross-sectional study, 2022.","authors":"Ahmed A Amer, Samar A Amer, Amerah Badokhon, Sherif M Hammad, Mohamed A Wasfy, Misha Khan, Tahani Ateyah Al-Harbi, Sadah Qamous Alobaid, Georgette Eskander, Amro Abdel-Azeem, Abdulmajeed Alshowair, Mohamed Sh Ramadan","doi":"10.1177/25151355241285594","DOIUrl":"https://doi.org/10.1177/25151355241285594","url":null,"abstract":"<p><strong>Background: </strong>Clear and trustworthy information is crucial to improving public acceptance of COVID-19 vaccinations, especially among pregnant women. Given the increased risk of severe viral pneumonia in pregnant women, it is critical to foster confidence in the vaccine's safety and understand any potential adverse events (AEs). So, we did this study in Jeddah, Saudi Arabia (SA), from March to May 2022 to compare women who did not get any doses of the COVID-19 vaccine during pregnancy (Group A) to women who did get at least one dose during pregnancy (Group B) regarding (1) the frequency, types, AEs, and management of its AEs of the COVID-19 vaccination; and (2) exploring pregnancy, delivery, and fetus-related complications (e.g., miscarriage, birth defects, and preterm labor).</p><p><strong>Methods: </strong>A cross-sectional study targeted 438 women who gave birth or were pregnant within the previous 8 weeks. Data was collected through face-to-face interviews with skilled nurses in 13 randomly selected primary healthcare facilities, using a validated, well-structured questionnaire that included the Centers for Disease Control (CDC) COVID-19 vaccination-related AEs. We analyzed the collected data using SPSS version 27.</p><p><strong>Results: </strong>Most participants were aged 25 to less than 35 (58.8%), and 287 (61.3%) were university graduates. There was no statistically significant difference among the studied groups regarding demographics. However, women in Group B had a significantly higher rate of abortions, oligohydramnios (24.4%), abnormal placentas (size and location), 103 (42.7%) abnormal fetal growth, 122 (53.7%) problems breastfeeding, blood pressure problems, and more cases of malaise, headaches, chest pain, breathing problems, and sleep problems than women in Group A. After the second and third doses, the confirmed post-vaccination COVID-19 rates in Group B were lower than those in Group A.</p><p><strong>Conclusion: </strong>The COVID-19 vaccine significantly reduces post-vaccination COVID-19. Although COVID-19 vaccine-related AES are prevalent, analgesics and antipyretics effectively treat most of them.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241285594"},"PeriodicalIF":0.0,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relative effectiveness of COVID-19 vaccine booster doses in people aged 65 and older-a retrospective cohort study in Türkiye.","authors":"Mehmet Akif Sezerol, Alican Sarisaltik","doi":"10.1177/25151355241285375","DOIUrl":"10.1177/25151355241285375","url":null,"abstract":"<p><strong>Background: </strong>Immunization in the elderly population is critical due to the high frequency of health outcomes related to COVID-19.</p><p><strong>Objectives: </strong>This study aimed to compare the effectiveness levels of COVID-19 vaccine schedules in preventing SARS-CoV-2 infection in the older adult group who received at least one booster dose.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>This study evaluated 8969 adults aged 65 and over in the Sultanbeyli district of İstanbul. COVID-19 vaccination and SARS-CoV-2 polymerase chain reaction testing data between January 14, 2021 and December 2, 2022 were obtained from the National Public Health Management System.</p><p><strong>Results: </strong>The median age of participants was 71 years. The vaccines were mostly administered as CoronaVac for the first and second doses (81.4% and 82.2%, respectively) and BNT162b2 for the third and fourth doses (61.8% and 73.1%, respectively). Turkovac was administered only in booster doses (third dose 0.6%, fourth dose 4.8%). The adjusted relative vaccine effectiveness (rVE) was found to be 61.8% (95% confidence interval (CI) 51.5-69.9) in two doses of inactivated vaccine and one dose of mRNA vaccine schedule compared to the homolog booster of CoronaVac primary vaccine schedule. In two booster doses receipts, the adjusted rVE was found to be 45.4% (95% CI 13.8-65.4) in three doses of inactivated and one dose mRNA vaccine schedule and 43.0% (95% CI 20.5-59.2) in two doses of inactivated and two doses of mRNA vaccines schedule compared to the two homolog boosters with CoronaVac primary vaccine schedule.</p><p><strong>Conclusion: </strong>In this study, the effectiveness of the mRNA vaccine as a booster dose was higher than that of the homologous boosters in participants receiving the CoronaVac primary series for those aged 65 and over.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241285375"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine coverage effectiveness among elderly with geographical information system mapping: what about Indonesia?","authors":"Widya Ratna Wulan, Evina Widianawati, Anis Tri Wahyuni","doi":"10.1177/25151355241285379","DOIUrl":"10.1177/25151355241285379","url":null,"abstract":"<p><strong>Background: </strong>The elderly are the next priority after health workers and public service workers get the COVID-19 vaccine to control morbidity and even mortality in the elderly who have a risk factor that is up to 60 times more severe than children.</p><p><strong>Objectives: </strong>This study aimed to spatially analyze the effectiveness of COVID-19 vaccine coverage among the elderly in Indonesia with geographic information system (GIS) mapping and to analyze the relationship between COVID-19 vaccine coverage in the elderly with the COVID-19 cure rate.</p><p><strong>Design: </strong>This quantitative study used secondary data on COVID-19 vaccination coverage in the elderly group of Central Java Province, Indonesia in 2021.</p><p><strong>Methods: </strong>Data were analyzed using a simple linear correlation test to test the relationship between variables with a 1,774,396 elderly sample size, then distributed using mapping of COVID-19 vaccination coverage using a GIS.</p><p><strong>Results: </strong>The relationship between COVID-19 vaccine dose-2 elderly coverage cure rate showed a strong relationship (<i>r</i> = 0.677) and a positive pattern. The coefficient value with a determination of 0.459 means that the regression line equation obtained can explain 45.90% of the variation in the COVID-19 cure rate. There was a significant relationship between COVID-19 vaccine elderly coverage and the COVID-19 cure rate (<i>p</i>-value = 0.005).</p><p><strong>Conclusion: </strong>Clinicians and public health workers should continue to encourage elderly vaccination at all recommended doses for eligible individuals.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241285379"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge, attitude, and acceptance of COVID-19 vaccine in pregnant women.","authors":"Arissara Kuptarak, Vorapong Phupong","doi":"10.1177/25151355241278832","DOIUrl":"https://doi.org/10.1177/25151355241278832","url":null,"abstract":"<p><strong>Background: </strong>Due to the COVID-19 situation, vaccination is a key factor in reducing the severity and transmission of the disease, especially in the vulnerable population, which includes pregnant women. Currently, various policies are in place to promote the vaccination of pregnant women against COVID-19; however, some pregnant women decline vaccination.</p><p><strong>Objectives: </strong>To study pregnant women's knowledge, attitude, and acceptance regarding the COVID-19 vaccine.</p><p><strong>Design: </strong>A cross-sectional study was conducted among pregnant women who received antenatal care at King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.</p><p><strong>Methods: </strong>Pregnant women who received antenatal care at King Chulalongkorn Memorial Hospital, Chulalongkorn University from November 2021 to April 2022 were included. The participants answered an online questionnaire through their electronic devices. Univariate and multivariate logistic regression analyses were performed to analyze the data.</p><p><strong>Results: </strong>A total of 500 pregnant women participated in this study. Among them, 67.4% and 81.4% had great knowledge and a positive attitude toward the COVID-19 vaccine, respectively, with scores of 80% or higher in each section. Of the 500 participants, 468 (93.6%) accepted to receive the COVID-19 vaccine. After adjusting for certain variables through multivariate analysis, the factor associated with the decision to receive the COVID-19 vaccine was having great knowledge about the vaccine (adjusted odds ratio (OR) 13.25, 95% confidence interval (CI) 2.45-71.61). However, the most significant factor associated with the decision to reject the COVID-19 vaccine was the recent COVID-19 infection (adjusted OR 0.11, 95% CI 0.02-0.62).</p><p><strong>Conclusion: </strong>The COVID-19 pandemic presents severe and life-threatening conditions for both pregnant women and their fetuses. The majority of the pregnant women in this study had great knowledge and acceptance of the vaccine and a positive attitude toward it. The pregnant women who had prior knowledge of the vaccine tended to accept to receive it during pregnancy, whereas those who recently contracted COVID-19 were hesitant to receive the vaccine.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241278832"},"PeriodicalIF":0.0,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11428176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}